Q-omics provides the consensus-scored UTP4 profile across patient tissues and cancer cell-line models. UTP4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, UTP4 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, UTP4 protein abundance shows 33,911 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where UTP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UTP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UTP4 survival associations across molecular data types. UTP4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UTP4 RNA expression–survival associations across cancer types. High UTP4 expression shows unfavorable associations in HNSC, LIHC, ACC, PAAD and MESO, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for UTP4 RNA expression.
This table summarizes UTP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UTP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UTP4 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, LUAD, LIHC and LUSC. The COAD box plot shows higher UTP4 RNA expression in tumor versus normal tissue (log2 FC = +2.055, t-test p < 0.001).
This table shows molecular features associated with UTP4 in patient tissues and cancer cell lines. In patient samples, UTP4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UTP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
